Therapeutic effect of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients.
The elevated estradiol/testosterone (E2/T) ratio had been proved to be a risk factor for coronary heart disease (CHD) in elderly males and to exert an adverse effect on lipid metabolism. We conducted a randomized cross-over study to determine the effect of Andriol, a new androgenic preparation, on plasma lipids and apolipoproteins. The results showed a significant difference in most parameters between patients receiving Andriol and the control group: in the former, serum T level was elevated significantly (P < 0.001), E2 level was unchanged (P > 0.05) and the E2/T ratio was reduced (P > 0.05). Blood levels of total cholesterol (TC) and triglyceride (TG) were lowered dramatically (P < 0.001) and high density lipoprotein cholesterol (HDL-ch) was raised (P < 0.05), but apolipoprotein-AI (APO-AI) and B (APO-B) levels remained unchanged. No obvious side effect was observed in those who took Andriol.
Wu
S
S
Dept. of Internal Medicine, Beijing Red Cross Chaoyang Hospital.
Weng
X
X
D000368:Aged; D016632:Apolipoprotein A-I / Q000378:metabolism*; D001055:Apolipoproteins B / Q000096:biosynthesis; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D014280:Triglycerides; D013739:Testosterone; D004958:Estradiol; D002784:Cholesterol; C010792:testosterone undecanoate